Long-term Outcomes (15 Years) After Subthalamic Nucleus Deep Brain Stimulation in Patients With Parkinson Disease.


Journal

Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060

Informations de publication

Date de publication:
02 Jun 2021
Historique:
received: 13 12 2020
accepted: 13 04 2021
entrez: 3 6 2021
pubmed: 4 6 2021
medline: 4 6 2021
Statut: aheadofprint

Résumé

To evaluate the effects of deep brain stimulation of the subthalamic nucleus (STN-DBS) in Parkinson disease (PD) patients on motor complications beyond 15 years after surgery. Data about motor complications, quality of life (QoL), activities of daily living, the UPDRS motor scores, dopaminergic treatment, stimulation parameters, and side effects of STN-DBS were retrospectively retrieved and compared between before surgery, at 1 year and beyond 15 years after bilateral STN-DBS. Fifty-one patients with 17.06 ± 2.18 years STN-DBS follow-up were recruited. Compared to baseline, the time spent with dyskinesia and the time spent in the off state were reduced by 75% (p<0.001) and by 58.7% (p<0.001), respectively. Moreover, dopaminergic drugs were reduced by 50.6% (p<0.001). The PDQL total score, and the emotional function and social function domains improved of 13.8% (p=0.005), 13.6% (p=0.01) and 29.9% (p<0.001), respectively. Few and mostly manageable device-related adverse events were observed during the follow-up. STN-DBS is still effective beyond 15 years from the intervention, notably with significant improvement in motor complications and stable reduction of dopaminergic drugs. Furthermore, despite the natural continuous progression of PD with worsening of levodopa-resistant motor and non-motor symptoms over the years, STN-DBS patients could maintain an improvement in QoL. This study provides Class IV evidence that, for patients with PD, STN-DBS remains effective at treating motor complications 15 years after surgery.

Identifiants

pubmed: 34078713
pii: WNL.0000000000012246
doi: 10.1212/WNL.0000000000012246
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2021 American Academy of Neurology.

Auteurs

Francesco Bove (F)

Movement Disorders Unit, Division of Neurology, CHU Grenoble Alpes, Grenoble, France.
Neurology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Department of Neurosciences, Università Cattolica del Sacro Cuore, Rome, Italy.

Delia Mulas (D)

Movement Disorders Unit, Division of Neurology, CHU Grenoble Alpes, Grenoble, France.
Institute of Neurology, Mater Olbia Hospital, Olbia, Italy.

Francesco Cavallieri (F)

Movement Disorders Unit, Division of Neurology, CHU Grenoble Alpes, Grenoble, France.
Neurology Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.

Anna Castrioto (A)

Movement Disorders Unit, Division of Neurology, CHU Grenoble Alpes, Grenoble, France.
Grenoble Institute of Neurosciences, University Grenoble Alpes, Inserm, U1216, Grenoble, France.

Stephan Chabardès (S)

Grenoble Institute of Neurosciences, University Grenoble Alpes, Inserm, U1216, Grenoble, France.
Division of Neurosurgery, Centre Hospitalier Universitaire (CHU), Grenoble Alpes University.

Sara Meoni (S)

Movement Disorders Unit, Division of Neurology, CHU Grenoble Alpes, Grenoble, France.
Grenoble Institute of Neurosciences, University Grenoble Alpes, Inserm, U1216, Grenoble, France.
Department of Health Sciences, University of Milan, Milan, Italy.

Emmanuelle Schmitt (E)

Movement Disorders Unit, Division of Neurology, CHU Grenoble Alpes, Grenoble, France.
Grenoble Institute of Neurosciences, University Grenoble Alpes, Inserm, U1216, Grenoble, France.

Amélie Bichon (A)

Movement Disorders Unit, Division of Neurology, CHU Grenoble Alpes, Grenoble, France.
Grenoble Institute of Neurosciences, University Grenoble Alpes, Inserm, U1216, Grenoble, France.

Enrico Di Stasio (E)

Cheminstry, Biocheminstry and Clinical Molecular Biology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Institute of Biochemistry and Clinical Biochemistry, Università Cattolica del Sacro Cuore, Rome, Italy.

Andrea Kistner (A)

Movement Disorders Unit, Division of Neurology, CHU Grenoble Alpes, Grenoble, France.
Grenoble Institute of Neurosciences, University Grenoble Alpes, Inserm, U1216, Grenoble, France.

Pierre Pélissier (P)

Movement Disorders Unit, Division of Neurology, CHU Grenoble Alpes, Grenoble, France.
Grenoble Institute of Neurosciences, University Grenoble Alpes, Inserm, U1216, Grenoble, France.

Eric Chevrier (E)

Movement Disorders Unit, Division of Neurology, CHU Grenoble Alpes, Grenoble, France.
Grenoble Institute of Neurosciences, University Grenoble Alpes, Inserm, U1216, Grenoble, France.

Eric Seigneuret (E)

Grenoble Institute of Neurosciences, University Grenoble Alpes, Inserm, U1216, Grenoble, France.
Division of Neurosurgery, Centre Hospitalier Universitaire (CHU), Grenoble Alpes University.

Paul Krack (P)

Department of Neurology, Bern University Hospital, Bern, Switzerland.

Valerie Fraix (V)

Movement Disorders Unit, Division of Neurology, CHU Grenoble Alpes, Grenoble, France.
Grenoble Institute of Neurosciences, University Grenoble Alpes, Inserm, U1216, Grenoble, France.

Elena Moro (E)

Movement Disorders Unit, Division of Neurology, CHU Grenoble Alpes, Grenoble, France elenamfmoro@gmail.com.
Grenoble Institute of Neurosciences, University Grenoble Alpes, Inserm, U1216, Grenoble, France.

Classifications MeSH